Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation.

Abstract:

BACKGROUND:Although lactulose and polyethylene glycol are osmotic laxatives widely used in the treatment of chronic constipation, no study has been conducted to compare their actions on the colonic bacterial ecosystem, which has an important influence on host health. AIM:To assess the effects of lactulose and polyethylene glycol on the composition and metabolic indices of the faecal flora in patients with chronic idiopathic constipation. METHODS:Sixty-five patients with chronic idiopathic constipation were included in this controlled, multi-centre, randomized, parallel-group study. Participants received lactulose (Duphalac) or polyethylene glycol-4000 (Forlax) powders for the first week at a fixed dosage at night (20 g/day); in the second week, patients were given the option to vary the dose according to efficacy and tolerance (10-30 g/day); for the last 2 weeks, treatment was administered at a fixed dosage based on the results of the second week (10-30 g/day). Stools were recovered for bacteriological analysis at days -1, 21 and 28. RESULTS:Clinical efficacy and tolerance were similar with both treatments. In the lactulose group, an increase in faecal bifidobacteria counts (P = 0.04) and beta-galactosidase activity (P < 0.001) was observed from day -1 to day 28, whereas, in the polyethylene glycol group, there was a decrease in total short-chain fatty acids (P = 0.02), butyrate (P = 0.04), acetate (P = 0.02) and faecal bacterial mass (P = 0.001). No differences were observed in stools with regard to the following parameters: counts of Lactobacillus, clostridial spores, Bacteroides and enterobacteria, pH, biliary acids and neutral sterol concentrations. CONCLUSIONS:Both lactulose and polyethylene glycol are efficacious and well tolerated. However, although lactulose can be considered as a pre-biotic in constipated patients, polyethylene glycol produces signs of decreased colonic fermentation in the stool.

journal_name

Aliment Pharmacol Ther

authors

Bouhnik Y,Neut C,Raskine L,Michel C,Riottot M,Andrieux C,Guillemot F,Dyard F,Flourié B

doi

10.1111/j.1365-2036.2004.01918.x

subject

Has Abstract

pub_date

2004-04-15 00:00:00

pages

889-99

issue

8

eissn

0269-2813

issn

1365-2036

pii

APT1918

journal_volume

19

pub_type

临床试验,杂志文章,多中心研究,随机对照试验
  • Review article: intra-oesophageal impedance monitoring for the assessment of bolus transit and gastro-oesophageal reflux.

    abstract:BACKGROUND:Intra-oesophageal impedance monitoring can be used to assess the clearance of a swallowed bolus (oesophageal transit) and to detect gastro-oesophageal reflux independent of its acidity. AIM:To discuss the clinical application of the impedance technique for the assessment of bolus transit and gastro-oesophag...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2008.03863.x

    authors: Conchillo JM,Smout AJ

    更新日期:2009-01-01 00:00:00

  • Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

    abstract:AIM:: To quantify through systematic review the pharmacokinetic profiles of the oral delayed release and sustained release mesalazine (5-aminosalicylate, 5ASA) formulations (Asacol, Salofalk, Mesasal, Claversal, Pentasa) and pro-drugs (sulfasalazine, olsalazine, balsalazide) used in the management of ulcerative colitis...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2003.01408.x

    authors: Sandborn WJ,Hanauer SB

    更新日期:2003-01-01 00:00:00

  • End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.

    abstract:BACKGROUND:Methotrexate (MTX) is one of the most frequently prescribed drugs in contemporary medicine with a well-recognised hepatotoxic potential, for which stringent laboratory and histological surveillance has long been advocated. AIM:To estimate the population burden of end-stage methotrexate-related liver disease...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12912

    authors: Dawwas MF,Aithal GP

    更新日期:2014-10-01 00:00:00

  • The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding.

    abstract:BACKGROUND:Recent data suggest a role for high-dose oral proton pump inhibition in ulcer bleeding. AIM:To compare the cost-effectiveness of oral high-dose proton pump inhibition to both high-dose intravenous proton pump inhibition and placebo administration. METHODS:The model adopted a 30-day time horizon, and focuse...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02035.x

    authors: Barkun AN,Herba K,Adam V,Kennedy W,Fallone CA,Bardou M

    更新日期:2004-07-15 00:00:00

  • Systematic review: herbal medicinal products for non-ulcer dyspepsia.

    abstract:BACKGROUND:Non-ulcer dyspepsia is predominantly a self-managed condition, although it accounts for a significant number of general practitioner consultations and hospital referrals. Herbal medicinal products are often used for the relief of dyspeptic symptoms. AIMS:: To critically assess the evidence for and against h...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.01339.x

    authors: Thompson Coon J,Ernst E

    更新日期:2002-10-01 00:00:00

  • Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis.

    abstract::Suppositories containing 300 mg 5-aminosalicylic acid (1.96 mmol) or 425 mg acetyl-5-aminosalicylic acid (1.96 mmol) were used in 40 patients with idiopathic proctitis to determine the efficacy of acetyl-5-aminosalicylic acid in treating this bowel inflammation. Each patient was treated with 5-aminosalicylic acid or a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1988.tb00668.x

    authors: van Hogezand RA,van Hees PA,van Gorp JP,van Lier HJ,Bakker JH,Wesseling P,van Haelst UJ,van Tongeren JH

    更新日期:1988-02-01 00:00:00

  • Meta-analysis: vasoactive medications for the management of acute variceal bleeds.

    abstract:BACKGROUND:Vasoactive medications such as vasopressin, somatostatin and their analogues (terlipressin, vapreotide and octreotide) are commonly used for the treatment of acute variceal bleeding. However, the risks and benefits of these interventions are not well understood. AIM:To undertake a meta-analysis of the effic...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2012.05088.x

    authors: Wells M,Chande N,Adams P,Beaton M,Levstik M,Boyce E,Mrkobrada M

    更新日期:2012-06-01 00:00:00

  • Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.

    abstract:BACKGROUND:Antibiotic resistance has increasingly been recognized as the major cause of treatment failure for Helicobacter pylori infection. New therapies for patients with metronidazole- or clarithromycin-resistant H. pylori are needed. AIM:To investigate the role of nitrofurantoin quadruple therapy for the treatment...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2001.00945.x

    authors: Graham DY,Saeed MA,Hoffman J,El-Zimaity HM,Kwon DH,Osato MS

    更新日期:2001-04-01 00:00:00

  • Systematic review with meta-analysis: the efficacy of tranexamic acid in upper gastrointestinal bleeding.

    abstract:BACKGROUND:Upper gastrointestinal bleeding is a common medical emergency associated with substantial mortality. Tranexamic acid may be effective for reducing mortality in upper gastrointestinal bleeding. AIM:To examine the effects of tranexamic acid in upper gastrointestinal bleeding by systematic review and meta-anal...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.15761

    authors: Twum-Barimah E,Abdelgadir I,Gordon M,Akobeng AK

    更新日期:2020-06-01 00:00:00

  • Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux disease.

    abstract:BACKGROUND:Cannabinoid (CB) receptors have been located in brain areas involved in the triggering of TLESRs as well as in the nodose ganglion from which vagal afferents emanate. The distribution of CB(1) receptors has been investigated in the human gastrointestinal mucosa, as expression of inflammatory process. AIM:To...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2010.04377.x

    authors: Calabrese C,Spisni E,Liguori G,Lazzarini G,Valerii MC,Strillacci A,Gionchetti P,Pagotto U,Campieri M,Rizzello F

    更新日期:2010-08-01 00:00:00

  • Review article: the epidemiology and prevention of gastric cancer.

    abstract:BACKGROUND:Gastric cancer can be divided into cardia and noncardia gastric adenocarcinoma (NCGA). Non cardia gastric cancer is a disease that has declined in global incidence but has remained as an extremely lethal cancer. AIM:To review recent advances in epidemiology and strategies in prevention of non cardia gastric...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12814

    authors: Fock KM

    更新日期:2014-08-01 00:00:00

  • Review article: Inflammatory bowel disease and genetics.

    abstract:INTRODUCTION:Inflammatory bowel disease (IBD) comprising ulcerative colitis (UC) and Crohn's disease (CD) is multigenic disorder. Tremendous progress has been achieved in unravelling the genetic background of IBD. It has led to the discovery of mutations in NOD2 associated with ileal CD and numerous other genes have be...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2007.03476.x

    authors: Weersma RK,van Dullemen HM,van der Steege G,Nolte IM,Kleibeuker JH,Dijkstra G

    更新日期:2007-12-01 00:00:00

  • Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.

    abstract:AIM:To evaluate and compare two 1-week low-dose triple therapies based on lansoprazole, amoxycillin and a macrolide in eradicating Helicobacter pylori. METHODS:Seventy consecutive patients, suffering from dyspeptic symptoms with H. pylori infection, were randomly allocated to one of two treatment groups: (A) (LAC; n =...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1996.d01-533.x

    authors: Cammarota G,Tursi A,Papa A,Montalto M,Veneto G,Cuoco L,Fedeli G,Gasbarrini G

    更新日期:1996-12-01 00:00:00

  • Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a systemic disorder that predominantly affects the bowels but is also associated with venous thromboembolism (VTE). AIM:To provide a quantitative assessment of the association of IBD with venous thromboembo...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.12294

    authors: Yuhara H,Steinmaus C,Corley D,Koike J,Igarashi M,Suzuki T,Mine T

    更新日期:2013-05-01 00:00:00

  • Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

    abstract:BACKGROUND:Deregulation of mammalian target of rapamycin (mTOR) signalling is common in human hepatocellular carcinoma (HCC). AIM:To determine the maximum tolerated dose (MTD) of the oral mTOR inhibitor everolimus in advanced HCC patients. METHODS:Patients with locally advanced or metastatic HCC (Child-Pugh class A o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.12132

    authors: Shiah HS,Chen CY,Dai CY,Hsiao CF,Lin YJ,Su WC,Chang JY,Whang-Peng J,Lin PW,Huang JD,Chen LT

    更新日期:2013-01-01 00:00:00

  • Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.

    abstract:BACKGROUND:The efficacy of interferon-alpha plus ribavirin treatment for patients not responding to interferon monotherapy is not well established. AIM:To assess the efficacy and safety of combination therapy with interferon-alpha 2a/2b plus ribavirin by performing a meta-analysis of randomized clinical trials. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1046/j.1365-2036.2002.01328.x

    authors: San Miguel R,Guillén F,Cabasés JM,Buti M

    更新日期:2002-09-01 00:00:00

  • Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre.

    abstract:BACKGROUND:Hepatitis vaccination is recommended in patients with chronic liver disease. AIM:To validate Current Procedural Terminology (CPT) codes and drug codes for hepatitis vaccination in administrative databases and determine vaccination rates in hepatitis C virus (HCV)-infected patients in a single large Veterans...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03827.x

    authors: Hachem CY,Kramer JR,Kanwal F,El-Serag HB

    更新日期:2008-11-01 00:00:00

  • The use of adalimumab in the management of refractory Crohn's disease.

    abstract:BACKGROUND:Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor-alpha. Recent clinical trials have demonstrated its efficacy in Crohn's disease; however, experience in clinical practice remains limited. AIM:To investigate the efficacy and safety of adalimumab in the clinical setting. METHODS...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2007.03583.x

    authors: Ho GT,Smith L,Aitken S,Lee HM,Ting T,Fennell J,Lees CW,Palmer KR,Penman ID,Shand AG,Arnott ID,Satsangi J

    更新日期:2008-02-15 00:00:00

  • Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.

    abstract:BACKGROUND:Proton pump inhibitors may interfere with the accuracy of the (13)C-urea breath test, but little information is available on the effect of standard doses of various proton pump inhibitors on this test. AIM:To evaluate the effect of short-term standard doses of omeprazole, lansoprazole and pantoprazole on th...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01192.x

    authors: Parente F,Sainaghi M,Sangaletti O,Imbesi V,Maconi G,Anderloni A,Bianchi Porro G

    更新日期:2002-03-01 00:00:00

  • Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.

    abstract:BACKGROUND:Historically, the beneficial effects of the nonsystemic oral agent rifaximin on various gastrointestinal (GI) disorders have been attributed to direct antibiotic activity on gut microbiota. However, data are accumulating to suggest that other nonantibacterial effects may be involved in rifaximin efficacy. A...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type:

    doi:10.1111/apt.13406

    authors: DuPont HL

    更新日期:2016-01-01 00:00:00

  • Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.

    abstract:BACKGROUND:Proton pump inhibitors (PPI) are widely used to treat acid-related disorders of the upper gastrointestinal tract. However, large observational studies have raised concerns about PPI-associated adverse events. In recent years, data from next-generation sequencing studies suggested that PPIs affect the composi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15604

    authors: Macke L,Schulz C,Koletzko L,Malfertheiner P

    更新日期:2020-03-01 00:00:00

  • Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.

    abstract:BACKGROUND:Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the intestine, which frequently require surgery for complications or failure of medical therapy. AIM:To seek evidence and provide direction for clinicians on optimal strategies to enable steroid free remission in inflammat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2008.03753.x

    authors: Panaccione R,Rutgeerts P,Sandborn WJ,Feagan B,Schreiber S,Ghosh S

    更新日期:2008-09-15 00:00:00

  • Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial.

    abstract:BACKGROUND:Misoprostol is known to be effective in stimulating intestinal transit both in healthy individuals and in patients with chronic constipation when evaluated in short-term trials. The aim of this study was to determine the utility of misoprostol in the long-term management of patients with chronic refractory c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1997.00237.x

    authors: Roarty TP,Weber F,Soykan I,McCallum RW

    更新日期:1997-12-01 00:00:00

  • The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience.

    abstract:AIM:To asses the efficacy and safety of ciclosporin in a paediatric population with inflammatory bowel disease. PATIENTS AND METHODS:Twenty-three Italian children treated with ciclosporin were studied retrospectively. The indications for treatment were severe unresponsive colitis, chronic active colitis or severe fist...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1365-2036.2002.01308.x

    authors: Barabino A,Torrente F,Castellano E,Gandullia P,Calvi A,Cucchiara S,De GL,Fontana M,Lionetti P,De Giacomo C,Gissi A

    更新日期:2002-08-01 00:00:00

  • Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort.

    abstract:BACKGROUND:Surveillance colonoscopy is recommended for inflammatory bowel disease (IBD) patients with longstanding extensive colitis (LEC). AIMS:To assess modalities and results of colonoscopic surveillance in a subset of CESAME cohort patients at high risk of colorectal cancer (CRC) and followed in university French ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04711.x

    authors: Vienne A,Simon T,Cosnes J,Baudry C,Bouhnik Y,Soulé JC,Chaussade S,Marteau P,Jian R,Delchier JC,Coffin B,Admane H,Carrat F,Drouet E,Beaugerie L

    更新日期:2011-07-01 00:00:00

  • Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients.

    abstract:BACKGROUND:Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice. AIM:To investigate whether clinical complications of cirrhosis may define different prognostic disease stages. METHODS:Analysis of the database from a ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12721

    authors: D'Amico G,Pasta L,Morabito A,D'Amico M,Caltagirone M,Malizia G,Tinè F,Giannuoli G,Traina M,Vizzini G,Politi F,Luca A,Virdone R,Licata A,Pagliaro L

    更新日期:2014-05-01 00:00:00

  • Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease.

    abstract:BACKGROUND:Intravenous esomeprazole may be beneficial for patients who cannot take oral medications. AIM:To compare intravenous esomeprazole with oral esomeprazole for effects on maximal acid output during pentagastrin stimulation in patients with gastro-oesophageal reflux disease symptoms. METHODS:In four separate o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2005.02659.x

    authors: Metz DC,Miner PB,Heuman DM,Chen Y,Sostek M

    更新日期:2005-11-01 00:00:00

  • Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma--a long-term follow-up study.

    abstract:BACKGROUND:The long-term outcome of percutaneous acetic acid injection (PAI) and percutaneous ethanol injection (PEI) for treating small hepatocellular carcinoma (HCC) remains unclear. AIM:To compare the long-term outcome of PAI vs. PEI for treating small HCC. METHODS:From July 1998 to July 2004, 125 patients with sm...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03702.x

    authors: Tsai WL,Cheng JS,Lai KH,Lin CP,Lo GH,Hsu PI,Yu HC,Lin CK,Chan HH,Chen WC,Chen TA,Li WL,Liang HL

    更新日期:2008-08-01 00:00:00

  • Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

    abstract:BACKGROUND:Sofosbuvir, an oral NS5B nucleotide polymerase inhibitor, is indicated for the treatment of patients infected with hepatitis C virus (HCV). AIM:To evaluate the long-term health economic outcomes of sofosbuvir + pegylated interferon alfa/ribavirin (pegIFN/RBV) compared with current treatments in patients inf...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12871

    authors: Saab S,Gordon SC,Park H,Sulkowski M,Ahmed A,Younossi Z

    更新日期:2014-09-01 00:00:00

  • Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging.

    abstract:BACKGROUND:Proton pump inhibitor (PPI) therapy is known to suppress gastric acid secretion. Thus PPI therapy may decrease gastric volume and gastric contents available for gastro-oesophageal reflux by decreasing acid secretion. AIM:To determine the effect of PPI therapy on the gastric volume after a standard meal. ME...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.03947.x

    authors: Babaei A,Bhargava V,Aalam S,Scadeng M,Mittal RK

    更新日期:2009-04-15 00:00:00